Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Baxter
Medtronic
Merck

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR TRAMETINIB DIMETHYL SULFOXIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Trametinib Dimethyl Sulfoxide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01725100 ↗ A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies Completed GlaxoSmithKline Phase 1 2013-02-05 This is an open-label, randomized, single-dose, 2-treatment, 2-period, 2-way crossover study with incomplete wash-out in subjects with solid tumors to determine the relative bioavailability of test formulation with lower dimethyl sulfoxide (DMSO) content as compared with standard reference formulation trametinib. Approximately 18 subjects will be randomized to receive either a single dose of Treatment A (standard target DMSO content [theoretical 11.3%] formulation of GSK1120212B) or a single dose of Treatment B (lower DMSO Content [approximately 9.5%] formulation of GSK1120212B) followed by a 7 day incomplete wash-out period, then a single dose of the other treatment. Administration of the dose under fasted conditions in Periods 1 and 2 will be only on Day 1 followed by 7 days of serial blood sampling for PK analysis of plasma trametinib. Safety assessments, including assessment of AEs, clinical laboratory (hematology and clinical chemistry) and vital signs, will be made throughout the study. After a subject completes the study, he or she may be eligible to enter study MEK114375, an open-label rollover study of trametinib (no wash-out period or follow-up visit required) and continue receiving trametinib. For those subjects who wish to discontinue or complete the current study and choose not enter the rollover study, a follow-up visit should be performed within 21 days after receiving the last dose of study treatment.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting GlaxoSmithKline Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting Novartis Pharmaceuticals Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT02101788 ↗ Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NRG Oncology Phase 2/Phase 3 2014-04-11 This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
NCT02101788 ↗ Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2/Phase 3 2014-04-11 This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
NCT02196181 ↗ Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 2 2014-07-22 This phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trametinib Dimethyl Sulfoxide

Condition Name

Condition Name for Trametinib Dimethyl Sulfoxide
Intervention Trials
Hematopoietic and Lymphoid Cell Neoplasm 5
Advanced Lymphoma 4
Advanced Malignant Solid Neoplasm 4
Refractory Lymphoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trametinib Dimethyl Sulfoxide
Intervention Trials
Neoplasms 7
Skin Neoplasms 5
Melanoma 5
Neoplasms, Plasma Cell 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trametinib Dimethyl Sulfoxide

Trials by Country

Trials by Country for Trametinib Dimethyl Sulfoxide
Location Trials
United States 209
United Kingdom 4
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trametinib Dimethyl Sulfoxide
Location Trials
Pennsylvania 11
Arizona 6
Maryland 6
Georgia 6
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trametinib Dimethyl Sulfoxide

Clinical Trial Phase

Clinical Trial Phase for Trametinib Dimethyl Sulfoxide
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 9
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trametinib Dimethyl Sulfoxide
Clinical Trial Phase Trials
Active, not recruiting 9
Completed 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trametinib Dimethyl Sulfoxide

Sponsor Name

Sponsor Name for Trametinib Dimethyl Sulfoxide
Sponsor Trials
National Cancer Institute (NCI) 12
GlaxoSmithKline 2
Novartis Pharmaceuticals 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trametinib Dimethyl Sulfoxide
Sponsor Trials
NIH 13
Industry 3
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Johnson and Johnson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.